EssilorLuxottica Showcases Integrated Vision Care at ARVO

EssilorLuxottica said it’s the first time that a coordinated scientific program has spanned the entire eye care continuum.

Combining capabilities in vision care and medical technologies – including Heidelberg Engineering, RetinAI, and Espansione – the group demonstrated how it integrates technologies, data, and clinical expertise within a unified, science-led ecosystem.

EssilorLuxottica said the “integrated model brings together myopia management and vision science, advanced diagnostics, AI-driven analytics, and technology-enabled therapeutic solutions to support more holistic, data-driven patient care”.

At ARVO, EssilorLuxottica presented more than 20 peer-reviewed scientific abstracts, which it said underscored the depth of its research

At ARVO, EssilorLuxottica presented more than 20 peer-reviewed scientific abstracts, which it said underscored the depth of its research.

“The integration of advanced imaging, AI-driven analytics, and therapeutic technologies is transforming how we understand and manage eye diseases,” said Norbert Gorny, Chief Scientific Officer at EssilorLuxottica.

“At ARVO 2026, we demonstrated how these capabilities enable a more connected, data-driven approach to eye care, from earlier detection to more informed patient management.”

Myopia Management

EssilorLuxottica presented eight abstracts on myopia management, focused on clinical outcomes, long-term efficacy, and mechanisms of progression control. A seven-year follow-up study of Essilor Stellest lenses in China demonstrated sustained efficacy, with 2.30 D less myopia progression and 0.92 mm less axial elongation¹ in adolescents up to 19 years old. These findings are supported by additional data, including a multicentre clinical trial in the United States^2-5 and recent FDA market authorisation.⁶ An analysis of 26 published studies confirmed consistent efficacy across study designs and populations, with reduced axial elongation compared to single vision lenses.⁷

Med-Tech Advances

EssilorLuxottica also showcased innovations in medical technologies, highlighting its role in enabling earlier insights, improving clinical decision making, and advancing more personalised care.

“Heidelberg Engineering’s pioneering work in multimodal imaging with ultra-high-resolution OCT and fully digital surgical microscopy is opening a new era in imaging and surgery. Together with RetinAI’s AI-powered insights and Espansione’s treatment options, we are transforming science into meaningful impact for patients, clinicians, researchers, and the future of eye care”, said Ettore Mosca, Head of Medical Technologies at EssilorLuxottica.